The Priority Review

Tag

JP-1366

1 story

  1. Clinical trials

    Onconic registers Phase 3 trial of JP-1366-based triple therapy for H. Pylori

    The study, led by Onconic Therapeutics Inc., plans to enroll 414 participants and begin recruiting on November 1, 2026. It is a multicenter, randomized, double-blind, active-controlled Phase III trial to evaluate the efficacy and safety of JP-1366-based triple therapy in H. Pylori-positive subjects.